Control of the cell cycle by mRNA degradation

通过 mRNA 降解控制细胞周期

基本信息

  • 批准号:
    7585209
  • 负责人:
  • 金额:
    $ 30.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-02-01 至 2012-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Title: Control of the cell cycle by mRNA degradation. Over the last period of this project we have extensively defined the role of the ribonucleoprotein endoribonuclease, RNase MRP, in mRNA degradation and cell cycle control. These studies have led us to discovering a new organelle, the TAM (Temporal Asymmetric MRP) body. We have found that this structure is P (processing) body "like". But in contrast to P bodies that are found throughout cells and the cell cycle, TAM bodies are temporally and spatially assembled organelles whose function is to degrade specific mRNAs at a discrete time and location in the cell cycle. P bodies or GW bodies have been implicated in regulating development, microRNAs and the cell cycle. RNase MRP is conserved throughout eukaryotes and mutations in the human RNA component have implicated this enzyme as an essential growth regulator. Human mutations cause Cartilage Hair Hypoplasia (CHH) a recessively inherited disorder characterized by short stature, brittle hair, anemia, immunodeficiency, and a predisposition to the development of lymphomas and other cancers. Data from our lab in collaboration with others has shown that human RNase MRP is also playing a role in destabilizing certain mRNAs. Failure to normally degrade certain mRNAs could easily cause the cell cycle delay seen in the human disease and the resulting phenotypes. Hence, these studies will have direct implications on human disease and pathogenesis. Experimentation will attack this problem in the yeast, Saccharomyces cerevisiae, an excellent RNase MRP model system that has proven to be highly conserved with the mammalian model systems. The specific aims have been designed to take advantages of the strengths in the yeast systems allowing us to learn more about RNase MRP, TAM bodies, and mRNA degradation. Our past history of using a simple genetic model system to lend insights into human disease considerably strengthens our proposal. In addition, our analysis of the molecular mechanism whereby complex genetic interactions lead to a phenotype and disease will provide much needed information as to how disease occurs in humans. PUBLIC HEALTH RELEVANCE: RNase MRP is conserved throughout eukaryotes and mutations in the human RNA component have implicated this enzyme as an essential growth regulator. Human mutations lead to Cartilage Hair Hypoplasia (CHH), a recessively inherited disorder characterized by short stature, brittle hair, anemia, immunodeficiency, and a predisposition to the development of lymphomas and other cancers. Based on our results from yeast it has already been shown that human RNase MRP is also playing a role in destabilizing certain mRNAs. This is data from our lab in collaboration with others. Failure to normally degrade certain mRNAs could easily cause the cell cycle delay seen in the human disease and the resulting phenotypes. Hence, these studies will have direct implications on human disease and pathogenesis. Over the last several years an immense amount has been learned about how cells control their division process. However the details and exact mechanism of many of the steps in the regulation of this process are still poorly understood. The incorrect regulation of cell division is the basis of all cancers. Understanding the details of how cell division is regulated and controlled is essential for controlling cancer and finding cures. RNase MRP is directly involved in the late stages of the cell division cycle by regulating mRNA levels of critical cell cycle molecules. The project will provide us with a better picture of how cells regulate the cell cycle and may provide some important new targets for antineoplastic agents.
描述(申请人提供):标题:通过信使核糖核酸降解来控制细胞周期。在这个项目的最后阶段,我们已经广泛地定义了核糖核蛋白内切核酸酶,核糖核酸酶MRP,在mRNA降解和细胞周期控制中的作用。这些研究使我们发现了一种新的细胞器--小体。我们发现这个结构是P(加工)体的“LIKE”。但与贯穿细胞和细胞周期的P小体不同,小体是在时间和空间上组装的细胞器,其功能是在细胞周期中的离散时间和位置降解特定的mRNAs。P小体或GW小体参与调节发育、microRNAs和细胞周期。 核糖核酸酶MRP在真核生物中是保守的,人类RNA成分的突变表明该酶是一种重要的生长调节因子。人类基因突变导致软骨毛发发育不良(CHH),这是一种隐性遗传性疾病,特征是身材矮小、头发脆弱、贫血、免疫缺陷,以及容易发生淋巴瘤和其他癌症。我们实验室与其他实验室合作的数据表明,人类RNase MRP也在破坏某些mRNAs的稳定方面发挥作用。如果不能正常降解某些mRNA,很容易导致人类疾病中出现的细胞周期延迟和由此产生的表型。因此,这些研究将对人类疾病和发病机制有直接的影响。 实验将在酵母中解决这个问题,酿酒酵母是一个优秀的RNase MRP模型系统,已被证明与哺乳动物模型系统高度保守。设计的具体目标是利用酵母系统的优势,使我们能够更多地了解核糖核酸酶MRP、小体和信使核糖核酸降解。我们过去使用简单的基因模型系统来洞察人类疾病的历史极大地加强了我们的提议。此外,我们对复杂遗传相互作用导致表型和疾病的分子机制的分析将提供关于疾病如何在人类发生的迫切需要的信息。 公共卫生相关性:核糖核酸酶MRP在真核生物中是保守的,人类RNA成分的突变表明该酶是一种重要的生长调节因子。人类突变会导致软骨毛发发育不良(CHH),这是一种隐性遗传性疾病,特征是身材矮小、毛发脆弱、贫血、免疫缺陷,并容易发生淋巴瘤和其他癌症。根据我们对酵母的研究结果,已经表明人类核糖核酸酶MRP也在破坏某些mRNAs的稳定方面发挥作用。这是我们实验室与其他人合作的数据。如果不能正常降解某些mRNA,很容易导致人类疾病中出现的细胞周期延迟和由此产生的表型。因此,这些研究将对人类疾病和发病机制有直接的影响。 在过去的几年里,人们已经了解了大量关于细胞如何控制其分裂过程的知识。然而,这一过程中许多步骤的细节和确切机制仍然知之甚少。细胞分裂的不正确调控是所有癌症的基础。了解细胞分裂是如何调控和控制的细节对于控制癌症和寻找治疗方法至关重要。核糖核酸酶MRP通过调节细胞周期关键分子的mRNA水平,直接参与细胞分裂周期的后期。该项目将为我们更好地了解细胞如何调节细胞周期,并可能为抗肿瘤药物提供一些重要的新靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK E SCHMITT其他文献

MARK E SCHMITT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK E SCHMITT', 18)}}的其他基金

Control of the cell cycle by mRNA degradation.
通过 mRNA 降解控制细胞周期。
  • 批准号:
    6844873
  • 财政年份:
    2003
  • 资助金额:
    $ 30.62万
  • 项目类别:
Control of the cell cycle by mRNA degradation.
通过 mRNA 降解控制细胞周期。
  • 批准号:
    6698098
  • 财政年份:
    2003
  • 资助金额:
    $ 30.62万
  • 项目类别:
Control of the cell cycle by mRNA degradation.
通过 mRNA 降解控制细胞周期。
  • 批准号:
    7007265
  • 财政年份:
    2003
  • 资助金额:
    $ 30.62万
  • 项目类别:
Control of the cell cycle by mRNA degradation
通过 mRNA 降解控制细胞周期
  • 批准号:
    8016705
  • 财政年份:
    2003
  • 资助金额:
    $ 30.62万
  • 项目类别:
Control of the cell cycle by mRNA degradation.
通过 mRNA 降解控制细胞周期。
  • 批准号:
    6573711
  • 财政年份:
    2003
  • 资助金额:
    $ 30.62万
  • 项目类别:
Import of RNA into Mitochondria
将 RNA 导入线粒体
  • 批准号:
    6603457
  • 财政年份:
    2002
  • 资助金额:
    $ 30.62万
  • 项目类别:
Import of RNA into Mitochondria
将 RNA 导入线粒体
  • 批准号:
    6547545
  • 财政年份:
    2002
  • 资助金额:
    $ 30.62万
  • 项目类别:
Import of RNA into Mitochondria
将 RNA 导入线粒体
  • 批准号:
    6906446
  • 财政年份:
    2002
  • 资助金额:
    $ 30.62万
  • 项目类别:
Import of RNA into Mitochondria
将 RNA 导入线粒体
  • 批准号:
    7081269
  • 财政年份:
    2002
  • 资助金额:
    $ 30.62万
  • 项目类别:
Import of RNA into Mitochondria
将 RNA 导入线粒体
  • 批准号:
    6756516
  • 财政年份:
    2002
  • 资助金额:
    $ 30.62万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 30.62万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 30.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 30.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 30.62万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 30.62万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 30.62万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 30.62万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 30.62万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 30.62万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 30.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了